411 related articles for article (PubMed ID: 18801541)
41. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation.
Pepe P; Aragona F
Urology; 2007 Dec; 70(6):1131-5. PubMed ID: 18158033
[TBL] [Abstract][Full Text] [Related]
42. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
[TBL] [Abstract][Full Text] [Related]
43. Mass screening-based case-control study of diet and prostate cancer in Changchun, China.
Li XM; Li J; Tsuji I; Nakaya N; Nishino Y; Zhao XJ
Asian J Androl; 2008 Jul; 10(4):551-60. PubMed ID: 18478158
[TBL] [Abstract][Full Text] [Related]
44. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
45. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
Hegarty JM; Wallace M; Comber H
Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
[TBL] [Abstract][Full Text] [Related]
46. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372
[TBL] [Abstract][Full Text] [Related]
47. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
[TBL] [Abstract][Full Text] [Related]
48. Public awareness of prostate cancer and the prostate-specific antigen test.
Mainous AG; Hagen MD
Cancer Pract; 1994; 2(3):217-21. PubMed ID: 7519944
[TBL] [Abstract][Full Text] [Related]
49. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
50. Predictors of prostate cancer screening among health fair participants.
Chiu BC; Anderson JR; Corbin D
Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
[TBL] [Abstract][Full Text] [Related]
51. A framework for the identification of men at increased risk for prostate cancer.
Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL
J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625
[TBL] [Abstract][Full Text] [Related]
52. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels.
Yang JC; Tang J; Li J; Luo Y; Li Y; Shi H
Acad Radiol; 2008 Oct; 15(10):1291-7. PubMed ID: 18790401
[TBL] [Abstract][Full Text] [Related]
53. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
Loeb S; Roehl KA; Catalona WJ; Nadler RB
J Urol; 2007 Mar; 177(3):899-902. PubMed ID: 17296371
[TBL] [Abstract][Full Text] [Related]
54. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
55. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study.
Wada Y; Nakanishi J; Takahashi W; Kai N; Nakayama Y; Yamashita Y; Honda J; Ueda S
BJU Int; 2006 Oct; 98(4):794-7. PubMed ID: 16978274
[TBL] [Abstract][Full Text] [Related]
56. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
Coard KC; Skeete DH
BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
[TBL] [Abstract][Full Text] [Related]
57. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
58. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
59. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
Hutterer G; Perrotte P; Gallina A; Walz J; Jeldres C; Traumann M; Suardi N; Saad F; Bénard F; Valiquette L; McCormack M; Graefen M; Montorsi F; Karakiewicz PI
Eur J Cancer; 2007 May; 43(7):1180-7. PubMed ID: 17292604
[TBL] [Abstract][Full Text] [Related]
60. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.
Dai B; Ye DW; Kong YY; Shen YJ; Wang BH
Asian J Androl; 2008 Mar; 10(2):325-31. PubMed ID: 18097514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]